Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL

被引：0
|
作者：
Shanafelt, Tait D. [1 ]
Lanasa, Mark C. [2 ]
Zent, Clive S. [1 ]
Leis, Jose F. [3 ]
Call, Timothy G. [1 ]
LaPlant, Betsy R.
Tun, Han [4 ]
Bowen, Deborah A. [1 ]
Jelinek, Diane F. [5 ]
Hanson, Curtis A. [6 ]
Kay, Neil [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Mayo Clin Arizona, Div Hematol & Med Oncol, Scottsdale, AZ USA
[4] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA
[5] Mayo Clin, Dept Immunol, Rochester, MN USA
[6] Mayo Clin, Div Hematopathol, Dept Lab Med, Rochester, MN USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1665 / 1666
页数：2
相关论文
共 50 条
  • [41] CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Lundin, J
    Björkholm, M
    Celsing, F
    Hale, G
    Hjalmar, V
    Kimby, E
    Tullgren, O
    Waldman, H
    Mellstedt, H
    Österborg, A
    ANNALS OF ONCOLOGY, 2000, 11 : 96 - 96
  • [42] CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Mellstedt, H
    Österborg, A
    Lundin, J
    Björkholm, M
    Celsing, F
    Hagberg, H
    Hast, R
    Hjalmar, V
    Kimby, E
    Luthman, M
    Tullgren, O
    Werner, B
    BLOOD, 1998, 92 (10) : 490A - 490A
  • [43] 2-CHLORODEOXYADENOSINE (CDA) FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)
    DELANNOY, A
    MARTIAT, P
    GALA, JL
    DENEYS, V
    FERRANT, A
    BOSLY, A
    SCHEIFF, JM
    MICHAUX, JL
    LEUKEMIA, 1995, 9 (07) : 1130 - 1135
  • [44] Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial
    Jain, Nitin
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Bose, Prithviraj
    Estrov, Zeev
    Jabbour, Elias J.
    Konopleva, Marina
    Alvarado, Yesid
    Kadia, Tapan
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Cortes, Jorge E.
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Garg, Naveen
    Wang, Xuemei
    Fru, Nina
    Cruz, Nichole
    Gandhi, Varsha
    Plunkett, William
    Kantarjian, Hagop M.
    Keating, Michael J.
    Wierda, William G.
    BLOOD, 2017, 130
  • [45] A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia
    Kay, Neil E.
    Strati, Paolo
    LaPlant, Betsy R.
    Leis, Jose F.
    Nikcevich, Daniel
    Call, Timothy G.
    Pettinger, Adam M.
    Lesnick, Connie E.
    Hanson, Curtis A.
    Shanafelt, Tait D.
    ONCOTARGET, 2016, 7 (48) : 78269 - 78280
  • [46] Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia
    Lampson, Benjamin L.
    Kim, Haesook T.
    Davids, Matthew S.
    Abramson, Jeremy S.
    Freedman, Arnold S.
    Jacobson, Caron A.
    Armand, Philippe
    Joyce, Robin M.
    Arnason, Jon E.
    Rassenti, Laura Z.
    Kipps, Thomas J.
    Huang, Samantha
    Fein, Joshua
    Hanna, John
    Fernandes, Stacey Marie
    Fisher, David C.
    Brown, Jennifer R.
    BLOOD, 2017, 130
  • [47] A phase Ib/II study of duvelisib in combination with FCR (dFCR) in previously untreated, younger patients with CLL
    Davids, Matthew S.
    Kim, Haesook T.
    Hanna, John
    Cowen, Leslie
    Francoeur, Karen
    Hellman, Jeffrey
    Arnason, Jon
    Odejide, Oreofe
    Armand, Philippe
    Fisher, David
    Brown, Jennifer
    LEUKEMIA & LYMPHOMA, 2017, 58 : 225 - 225
  • [48] Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
    Al-Kali, Aref
    Wierda, William
    Keating, Michael
    O'Brien, Susan
    JOURNAL OF BLOOD MEDICINE, 2010, 1 : 115 - 122
  • [49] Early Treatment with Ofatumumab in Patients with High-Risk CLL
    Desikan, Sai Prasad
    Keating, Michael J.
    Ferrajoli, Alessandra
    Jain, Nitin
    Ohanian, Maro
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Konopleva, Marina
    Kadia, Tapan M.
    O'Brien, Susan
    Estrov, Zeev E.
    Thomas, Deborah A.
    Burger, Jan A.
    Thompson, Philip A.
    Wierda, William G.
    BLOOD, 2022, 140 : 9876 - 9878
  • [50] A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Flinn, Ian W.
    Harwin, William N.
    Macias-Perez, Ines M.
    Tucker, Patrick S.
    Waterhouse, David M.
    Papish, Steven W.
    Jones, Jeffrey A.
    Hainsworth, John D.
    Byrd, John C.
    BLOOD, 2011, 118 (21) : 1673 - 1673
12345